Early recognition of GBS with fluctuations and acute-onset CIDP
Date published: May 9, 2024
In 10% of the patients with GBS, secondary fluctuations occur and in 5% the diagnosis is eventually changed to acute-onset CIDP (A-CIDP). Early recognition of patients at risk for fluctuations or A-CIDP is important, because alternative treatment options can be considered in these patients.
In this study, we aim to describe the clinical features of GBS with fluctuations and A-CIDP and define early distinguishing factors between GBS with fluctuations and A-CIDP. The study results will be helpful to enable an early identification and start of appropriate treatment in GBS patients with fluctuations and patients with A-CIDP.
A list of research articles
-
The role of B lymphocytes in the progression of chronic immune-mediated neuropathies
-
Study on CIDP
In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.
-
-
Detecting anti-paranodal antibodies
-
Study on GBS
My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).
-
-
Time to treatment study
-
Study on GBS
In this project, we aim to describe the current practice of time to treatment. We also assess the association with functional outcome in patients with GBS who received first-line treatment with intravenous immunoglobulin or plasma exchange. This study is performed using data from the International GBS Outcome Study (IGOS).
-
